ArticleThe Lancet regional health. Europe2025

Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies.

Hugo Jourdain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.